Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 13, 2020January 13, 2020

Generation Bio Raises $110 Million for Non-viral Gene Therapy for Hemophilia A, Other Diseases

News

Generation Bio said it received $110 million in funding to bring its innovative, non-viral gene therapy for lead programs hemophilia A and phenylketonuria into investigational new drug-enabling clinical trials. Gene ... Read more

January 6, 2020January 6, 2020

Pfizer Taking over Development of Potential Gene Therapy SB-525, Advancing into Phase 3 Trials

News

Sangamo Therapeutics has handed over the development of SB-525, a gene therapy for hemophilia A, to Pfizer, which will now advance the therapy into Phase 3 clinical trials. Pfizer ... Read more

December 11, 2019December 11, 2019

Bayer, Children’s Hospital of Philadelphia Working on Non-replacement Hemophilia Therapies

News

Bayer has entered into a three-year research partnership with the Children’s Hospital of Philadelphia to develop small molecule non-replacement therapies as a first-line and less burdensome oral treatment for ... Read more

October 30, 2019October 30, 2019

Professional Help Essential for Parents Telling Daughters of Hemophilia Carrier Risk, Study Reports

News

An interview-based study from Japan found professional support was necessary when mothers inform their daughters they might be carriers for hemophilia, as the women found themselves “not knowing what ... Read more

October 16, 2019October 16, 2019

Bone Defects Detected at Birth, After Injury, in Mouse Models of Hemophilia A and B, Study Shows

News

Bone defects were seen since birth — and following injury — in mouse models of hemophilia A and B, but not in Von Willebrand (VWD) disease mice, a study ... Read more

October 4, 2019October 4, 2019

DalcA, Under-skin Injectable Factor IX Prophylactic, Showing Potential in Phase 2 Trial, Catalyst Says

News

A preventive treatment for hemophilia B called dalcinonacog alfa (DalcA) led to an increase of more than 12% in the levels of factor IX in two patients with severe disease treated in ... Read more

September 13, 2019September 13, 2019

Freeline’s Gene Therapy for Hemophilia B Is Promising, Phase 1/2 Data Show

News

Data from the first two patients treated with FLT180a, Freeline’s single-infusion gene therapy for patients with hemophilia B, showed a rise in levels of clotting factor IX to 40%, with ... Read more

August 28, 2019August 28, 2019

FDA Grants Sigilon Therapeutic’s SIG-001 Orphan Drug Status for Hemophilia A

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Sigilon Therapeutics’ candidate cell therapy, called SIG-001, for hemophilia A. Orphan drug status aims to encourage therapies for rare and ... Read more

August 14, 2019August 14, 2019

Variations in Certain Immune Genes May Help Predict Risk for Developing FVIII Inhibitors in Hemophilia A

News

Genetic variations in certain immune-related genes, namely the HLA and IL-10 genes, are linked with an increased risk for developing inhibitors against factor VIII replacement therapies in patients with ... Read more

August 5, 2019August 5, 2019

Parent’s Sense of Burden Higher When Child Overweight and Has Inhibitors, Study Finds

News

The presence of inhibitors and excessive body weight increase the sense of disease burden felt by parents of children with moderate to severe hemophilia, a study reports. The study ... Read more

Pin It on Pinterest